Snowball logo
logo
BNGO_logo

Bionano Genomics, Inc. ORD SHS

₽116.00₽0.00  (0%)
Estimate
EPS
-381.746
Beta
0.348
Growth
Revenue, YoY
22.13%
Net income, YoY
-8.95%
FCF, YoY
-34.78%
Forecast
EPS (FWD)
-0.97
About the company
Ticker
BNGO-RM
ISIN
US09075F1075
Country
Other
Sector (GICS)
Healthcare
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Frequently asked questions

What sector does Bionano Genomics, Inc. ORD SHS (BNGO-RM) operate in?

Bionano Genomics, Inc. ORD SHS belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.

What is Bionano Genomics, Inc. ORD SHS (BNGO-RM) current stock price?

As of the latest data, Bionano Genomics, Inc. ORD SHS stock price is RUB 116.00, with a previous close of RUB 116.00.

What is Bionano Genomics, Inc. ORD SHS (BNGO-RM) current market capitalization?

Bionano Genomics, Inc. ORD SHS market cap is approximately 16.63 million.

What is Bionano Genomics, Inc. ORD SHS (BNGO-RM) Earnings Per Share (EPS)?

The trailing EPS is -RUB 381.75, and the forward EPS is -RUB 0.97.

What is Bionano Genomics, Inc. ORD SHS (BNGO-RM) EBITDA?

Bionano Genomics, Inc. ORD SHS EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -402.94 million.

Does Bionano Genomics, Inc. ORD SHS (BNGO-RM) pay dividends?

No. Bionano Genomics, Inc. ORD SHS does not pay a dividend.

How did Bionano Genomics, Inc. ORD SHS (BNGO-RM) perform in its most recent earnings report?

In the last report (June 30, 2026), Bionano Genomics, Inc. ORD SHS posted an EPS surprise of 8.57% and a revenue surprise of 8,501.63%.

When is Bionano Genomics, Inc. ORD SHS (BNGO-RM) next earnings report?

Bionano Genomics, Inc. ORD SHS is expected to release its next earnings report on September 30, 2026.

What is Bionano Genomics, Inc. ORD SHS (BNGO-RM) beta (volatility) score?

Bionano Genomics, Inc. ORD SHS has a beta of 0.348, indicating lower volatility than the overall market.